Latest disclosed round
Series B
- Date
- 2024-10-01
- Amount
- GBP 80m
- Sector
- Biotech & techbio
- Companies House
- 12543677
Series B
Purespring Therapeutics
Gene therapy (kidney disease)
CandidateSeries BLondon
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
5 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2024-10-01 | Series B | £80M / $105M | Sofinnova Partners, Gilde Healthcare, Forbion, British Patient Capital, Syncona |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.